TY - JOUR
T1 - Managing high-risk CLL during transition to a new treatment era
T2 - Stem cell transplantation or novel agents?
AU - Dreger, Peter
AU - Schetelig, Johannes
AU - Andersen, Niels
AU - Corradini, Paolo
AU - Van Gelder, Michel
AU - Gribben, John
AU - Kimby, Eva
AU - Michallet, Mauricette
AU - Moreno, Carol
AU - Stilgenbauer, Stephan
AU - Montserrat, Emili
PY - 2014/12/18
Y1 - 2014/12/18
N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [
AB - Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [
UR - http://www.scopus.com/inward/record.url?scp=84919469417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919469417&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-07-586826
DO - 10.1182/blood-2014-07-586826
M3 - Article
C2 - 25301705
AN - SCOPUS:84919469417
VL - 124
SP - 3841
EP - 3849
JO - Blood
JF - Blood
SN - 0006-4971
IS - 26
ER -